The optimization of the immunogenicity of antigens delivered by the mucosal route is a main priority, since mucosal vaccination leads to the stimulation of immune responses at the sites where the first line of defense against infections is laid. This results in protection not only against disease, but also against infection (i.e. colonization), thereby reducing the risk of horizontal transfer from infected individuals to susceptible hosts.
Therefore, this project focuses on the development of new adjuvants, which are amenable for mucosal vaccination. Their underlying mechanisms of action are elucidated to facilitate the fine tuning of the elicited responses, as well as to assess the potential risk of side effects associated with their use in humans. The most promising candidates are been exploited for the development of vaccine candidates against specific diseases.
- Vakzinologie und angewandte Mikrobiologie- Prof. Dr. Carlos A. Guzmán
Geldgeber / Förderer